Lots of new MPN therapies are becoming available, but many are targeted for some of the rarer forms of the disease. Can they also help patients with the more common MPNs like essential thrombocythemia (ET) and polycythemia vera (PV)? It's quite possible that they can. In this video, Dr. Ruben Mesa of the Mayo Clinic shares his perspective based on recent research and analysis. Watch now.